Proton: Making the Invisible Visible

While continuous glucose monitoring has transformed diabetes care, monitoring other critical biomarkers remains challenging. Proton Intelligence, which just raised $7M in seed funding, aims to do for potassium what Dexcom did for glucose—but the path ahead is complex.

Key Points:

Proton's approach is particularly interesting because it targets a critical yet underserved medical need. Potassium imbalances can be life-threatening, but current monitoring solutions are either indirect (like AliveCor's cardiac activity approach) or invasive (like Renalyse's finger-prick tests). By developing a continuous monitoring solution, Proton could fundamentally change how chronic kidney disease is managed.

However, their challenge is two-fold. First, they must achieve the technical feat of accurate, continuous potassium monitoring—something that has eluded the medical device industry. Second, they need to navigate the complex regulatory landscape while maintaining a viable path to market. The fact that they've spent extensive time interviewing care teams (over 100 in-depth interviews) suggests they understand the need to balance technical innovation with practical implementation.

Today’s Sponsor

Private Market Access for Accredited Investors

UpMarket brings accredited investors closer to the potential tech giants of tomorrow. Trusted by over 500 investors, our platform has facilitated over $175M in investments in private companies like OpenAI, ByteDance, and SpaceX. UpMarket simplifies access to exclusive deals that could help you redefine your investment portfolio. Embrace the future of investing with UpMarket and gain a foothold in nascent industries and sectors that are changing the world.

Join now

Quick Bites

🛡️ Mindgard Secures $8M for AI Security:

🧠 Stem AI Emerges from Stealth:

.

💼 Aiwyn Lands $113M for Accounting Tech:

Vocabulary

💡Each edition we’ll bring you a new “Startup word” to help bolster your vocabulary and understanding of the subject!

Biomarker: noun /ˈbīōˌmärkər/

Definition: A measurable substance in an organism whose presence indicates some phenomenon such as disease, infection, or environmental exposure.

Why It Matters: In the medical device startup world, identifying and accurately measuring biomarkers is crucial for developing effective monitoring solutions.

In Action: Proton's focus on potassium as a biomarker demonstrates how startups can create value by making critical health indicators more accessible and measurable.

Startup Shutdown Of The Day :(

Fisker: When Vision Collides With Execution

EV maker Fisker's bankruptcy marks one of this year's most dramatic startup failures, highlighting the perils of scaling hardware companies too quickly.

Key Points:

Fisker's collapse reveals fundamental flaws in their approach to building an auto company. While they had impressive design capabilities and strong initial demand, they failed at basic operational functions like quality control, payment tracking, and customer service. Their rush to scale production before establishing solid foundations proved fatal.

The most telling detail might be their temporary loss of track of customer payments—a basic business function that suggests deeper organizational issues. This wasn't just about building cars; it was about building a company, and Fisker seemed to prioritize growth over fundamental business processes.

EV maker Fisker's bankruptcy marks one of this year's most dramatic startup failures, highlighting the perils of scaling hardware companies too quickly.

Key Points:

Fisker's collapse reveals fundamental flaws in their approach to building an auto company. While they had impressive design capabilities and strong initial demand, they failed at basic operational functions like quality control, payment tracking, and customer service. Their rush to scale production before establishing solid foundations proved fatal.

The most telling detail might be their temporary loss of track of customer payments—a basic business function that suggests deeper organizational issues. This wasn't just about building cars; it was about building a company, and Fisker seemed to prioritize growth over fundamental business processes.

Another Sponsor

Missed out on crypto? Here’s the good news.

If you feel like you missed out on Bitcoin or crypto, there's good news on the horizon. James Altucher, a genius investor who famously called the success of Bitcoin in 2011, says AI is the next big thing—and it’s going to be 10X bigger than crypto. According to Altucher, a once-in-a-lifetime "wealth window" in AI is opening, but it will close soon

See what he's predicting here